Revel Michel's Form 4 filing
NewcelX Ltd. (NCEL) · filed Apr 29, 2026
- Accession no.
- 0001213900-26-049273
- Filed
- Apr 29, 2026
- Trade date
- Apr 27, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $150.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Revel MichelCIK 0002095518 | Director, Officer (CSO and Director), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Common Shares, par value CHF 0.05 per share | PPurchaseAcquired | +54,545 | $2.75F1 | +$149,998.75 | 957,530 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Common Shares, par value CHF 0.05 per share | PPurchaseAcquired | +76,363 | –F1 | – | 76,363 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The combined purchase price per one common share, par value CHF 0.05 per share ("Common Share"), and accompanying one warrant to purchase Common Share was $2.75.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.